Berkeley, CA – Ray Therapeutics has announced the appointment of Michael Murtagh as Chief Regulatory Officer. About Ray Therapeutics: Ray Therapeutics is a clinical-stage biopharmaceutical company dedicated to advancing optogenetic gene therapies for the restoration of vision in patients suffering from severe retinal degeneration. The company’s innovative approach involves delivering a bioengineered, highly light-sensitive protein to targeted retinal cells, aiming to improve visual function irrespective of the underlying genetic mutation. Their lead candidate, RTx-015, is currently undergoing a Phase 1 clinical trial for individuals with retinitis pigmentosa, a genetic disease leading to progressive blindness. Additionally, Ray Therapeutics is developing a second program, RTx-021, which is entering clinical trials for Stargardt disease and geographic atrophy, targeting retinal bipolar cells. Headquartered in Berkeley, California, the company is focused on building a leadership team with the expertise necessary to develop differentiated, best-in-class optogenetic therapies for patients experiencing vision loss.

For more information on Ray Therapeutics please visit: https://raytherapeutics.com/

Ray Therapeutics
2607 7th St. Suite B
Berkeley, CA 94710
Phone: 858-617-8610
LinkedIn Page: https://www.linkedin.com/company/ray-therapeutics-inc/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved